NeuroSense Therapeutics (NASDAQ:NRSN) Stock Dropped to Neutral by HC Wainwright

NeuroSense Therapeutics (NASDAQ:NRSN) was downgraded by equities researchers at HC Wainwright from a “buy” rating to a “neutral” rating in a research note issued to investors on Monday, Benzinga reports.

A number of other brokerages also recently weighed in on NRSN. Roth Capital downgraded shares of NeuroSense Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of NeuroSense Therapeutics in a research report on Wednesday. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $170.00.

NeuroSense Therapeutics Price Performance

NASDAQ NRSN traded down $0.71 during trading hours on Monday, reaching $1.28. 378,576 shares of the company’s stock traded hands, compared to its average volume of 15,668. NeuroSense Therapeutics has a 52-week low of $1.10 and a 52-week high of $25.40. The firm has a market cap of $2.44 million, a PE ratio of -0.12 and a beta of 1.75. The firm has a 50-day simple moving average of $5.44 and a 200 day simple moving average of $12.90.

Institutional Investors Weigh In On NeuroSense Therapeutics

An institutional investor recently bought a new position in NeuroSense Therapeutics stock. Yorkville Advisors Global LP acquired a new position in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 78,000 shares of the company’s stock, valued at approximately $56,160. Yorkville Advisors Global LP owned about 0.21% of NeuroSense Therapeutics as of its most recent SEC filing. 1.04% of the stock is currently owned by institutional investors and hedge funds.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd. is an Israel-based clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company’s research is aimed at addressing multiple biological mechanisms associated with conditions such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease.

Its lead investigational product, PrimeC, is a proprietary oral combination formulation of ciprofloxacin and celecoxib designed to target pathways implicated in ALS, including neuroinflammation and RNA regulation.